知镜 Cognispect · 医学文献与研究工作台

Cystic Fibrosis

Savant A, Bojanowski CM, Upadia J.
· 2026-10-01 · PMID 20301428

文献摘要

Clinical characteristics Cystic fibrosis (CF) is a multisystem disease affecting epithelia of the respiratory tract, pancreas, intestine, hepatobiliary system, and exocrine sweat glands. Morbidities include progressive obstructive pulmonary disease with bronchiectasis, recurrent sinusitis and bronchitis, exocrine pancreatic deficiency and malnutrition, pancreatitis, gastrointestinal manifestations (meconium ileus, rectal prolapse, distal intestinal obstructive syndrome), liver disease, diabetes, osteopenia/osteoporosis, male infertility due to hypoplasia or aplasia of the vas deferens, and reduced fertility or infertility in some women. By 2025, 95% of individuals with CF were eligible for targeted therapies, which has significantly altered the long-term course of the disease with a reduced overall disease burden. The impact is most evident in fewer hospitalizations, reduced clinic visits, and a decreased need for lung transplantation, all of which are associated with improved survival. While the CF disease phenotype has overall become less severe and more heterogenous in the era of highly effective CF transmembrane conductance regulator (CFTR) modulator therapy, pulmonary disease is the major cause of morbidity and mortality in CF. Diagnosis/testing The diagnosis of CF is established in a proband with (1) elevated immunoreactive trypsinogen on newborn screening, signs and/or symptoms suggestive of CF, or family history of CF; AND (2) evidence of an abnormality in CFTR function: sweat chloride ≥60 mmol/L on sweat chloride testing, biallelic CFTR CF-causing pathogenic variants, or nasal transmembrane epithelial potential difference measurement consistent with CF. Management Targeted therapies: CFTR modulator therapy is available for individuals with responsive CFTR variants. These should be prescribed and managed by a clinician with CF expertise, particularly when initiating therapy. Supportive care: Newborns – management by a CF specialist or CF care center; airway clearance instruction; encouraging feeding with breast milk; routine vaccinations; contact precautions with every clinical encounter; antibiotics for bacterial suppression and treatment; nutrition management; pancreatic enzyme replacement; nutrient-dense food and supplements; fat-soluble vitamin supplements; laxative treatment as needed with surgical management for bowel obstruction; salt supplementation as needed. After the newborn period – airway clearance; pulmonary treatment (bronchodilator, hypertonic saline, dornase alfa, airway clearance, and aerosolized antibiotic); standard treatments for pneumothorax or hemoptysis; double lung transplant for those with advanced lung disease; routine vaccinations including influenza; contact precautions; antibiotics for bacterial suppression and treatment; antibiotics and/or surgical intervention for nasal/sinus symptoms; nutrition management; pancreatic enzyme replacement; nutrient-dense food and supplements; fat-soluble vitamin supplements; laxative treatment as needed with surgical management for bowel obstruction; standard treatments for gastroesophageal reflux disease; liver transplant when indicated; management of CF-related diabetes mellitus by an endocrinologist; assisted reproductive technologies (ART) for infertility; salt supplementation; standard treatments for associated mental health issues. Surveillance: Frequent assessment by a CF specialist to monitor for new or worsening manifestations; pulmonary function testing frequently after age five years; consider chest CT to assess for bronchiectasis every two years or as needed; cultures of respiratory tract secretions at least every three months; non-tuberculosis mycobacterium culture and measurement of serum immunoglobulin E annually or as indicated; annual complete blood count with differential; ENT assessment as needed; monitor growth and gastrointestinal manifestations at each visit; fecal elastase as needed; annual serum vitamin A, D, E, and prothrombin time (as a marker of vitamin K); colon cancer screening at least every five years beginning at age 40 years (beginning at age 30 years in transplant recipients); annual liver function tests; liver ultrasound with Doppler every two years starting at age three years; annual measurement of random blood glucose; annual two-hour glucose tolerance test beginning at age ten years; dual-energy x-ray absorptiometry scan in adolescence in those with risk factors for osteopenia, then every one to five years; infertility assessment as needed; annual electrolytes, blood urea nitrogen, and creatinine; annual assessment for depression and anxiety. Agents/circumstances to avoid: Environmental smoke and inhalants including electronic nicotine delivery products, exposure to respiratory infections, and dehydration. Evaluation of relatives at risk: Sweat chloride testing is recommended for all at-risk sibs of a proband to identify as early as possible those who should be referred to a CF center for initiation of early treatment. Genetic counseling CF is inherited in an autosomal recessive manner. If both parents are known to be heterozygous for a CFTR pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial pathogenic variants. Heterozygotes may be at increased risk for respiratory manifestations and/or pancreatitis. Once the CFTR pathogenic variants have been identified in an affected family member, targeted heterozygote testing for at-risk relatives and prenatal/preimplantation genetic testing for CF are possible.

在知镜精读原文来源

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。